focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Unless they (the bod including jh/dg) have decided they’re happy with what we have and looking for the end game. Nxp001 hopefully keeps the lights on until the other 2 come to fruition?
Interested to see who/if we get a new CEO and what their plans are upon joining
When you’ve waited as long as you have what’s a few more weeks positives taken we could possibly be in discussions on nxp004 by the time results are out in January which were hinted at that they have gone well. Frustrating but happy to wait!!
Rank Who
1 jay12
2 Aim4Utopia
3 TaffEvans
4 goupplease
5 Soupdragon78
6 Filter29
7 Manabouttown
8 ForFXSake
9 Scaryone
10 chablard
11 mazik
12 yuyus
13 HaleSpur
14 Rob1967
15 @michelle_crypto
16 happyholder
17 Pettycash
18 Aberdeenman
19 GreggsStottie
20 Mozax
21 Infor1p
22 hiblue
23 findahappyplace
24 @aim_gravy
25 Screech777
26 whimax
27 Offshoresailor
28 ATrades
29 Kaneonaim
30 share_talk
31 Brooko19
32 Mars1
33 Inner-Harmony
34 chrisrainy
35 Mohsin15
36 mornington-oz
37 Doofu
38 Kiwi_
39 Jiving
40 Wressmycase
41 rnorth
42 Cdub1
43 @MInvestor50
44 olderbutwiser
45 Notperfect
46 JackpotJoywinner
47 Randomchancer
48 Hallowed
49 @AIMFruitStar
50 SPENCER1471
51 @Share_Talk
52 Chalmer15
53 SuperStockMan
54 aj242
55 TruthCaller
Lol!! What sad **** updates this!!
http://******************/rampchecker/rampcheckbytidm.php?search=Nfx
Rank Who
1 G_G_G
2 tonynorstrom1
3 GeneralLevy
4 share_talk
5 JAdam
6 Brooko19
7 @Share_Talk
8 @************
9 TSSZ
10 nomadicinvestor
11 LockerRoom
12 Moses151
13 Fastfood
14 SwearinNige
15 Austin14
16 miker444
17 harel
18 Milcait
19 BigBiteNow
20 tomhuk2000
21 jollygoodya
22 Backwoodsman
23 Kaneonaim
Lol!! What sad **** updates this!!
Literally tweeted this as I posted lol!!
#ICYMI: We announced on Friday that we have filed a new patent application, covering a new family of co-crystalline forms of NXP004.
See the full statement here: https://polaris.brighterir.com/public/nuformix/news/rns/story/rmnj3vw…
Soup is this an old study?
Value:
£43,814
Funded Period:
Jun 15 - Mar 16
Funder:
Innovate
Abstract
Funding
details The project will evaluate the feasibility of inhaled delivery of a cocrystal-enabled known drug
to treat idiopathic pulmonary fibrosis (IPF) in-vivo.
The 1st therapies for IPF - a growing disease (5000 UK patients diagnosed/year*) with high
mortality (50% die in 2-3 years of diagnosis*) were approved in 2014 (Pirfenidone &
Nintedanib). These new therapies do not prevent disease progression and as oral treatments
have highly undesirable side-effects. The project aims to show that by delivering a more
effective drug directly to the lung, the efficacy of treatment can be increased without side
effects. There are 4 innovative aspects:
1. Inhalation for IPF is a novel concept & enables drug delivery direct to the site of need,
increasing efficacy and minimising undesirable drug exposure. >80% of patients have the
lung function to use a dry powder inhaler (DPI)**.
2. The active ingredient will be Tranilast – a Japanese oral asthma drug with a strong safety
profile. Tranilast is also well validated as an anti-fibrotic agent and therefore has new potential
for use in IPF.
3. Cocrystal technology can improve key physical properties for drug molecules. Tranilast is
highly insoluble and cocrystal technology will improve lung solubility & biodistribution,
maximising performance. This cocrystal application would be a 1st for inhalation.
4. Bleomycin is an accepted IPF disease model but has limitations. The Lung Slice Culture
(LSC) model addresses its problems & reduces the number of animals used, but is less
validated. The 2 models have not been compared using the same drug. This novel combined
approach will further validate both the result and the LSC model for future studies.
5. The processes & devices used for DPI delivery in-vivo are limited and less validated than
other methods. The study will develop reliable processes to investigate the delivery concept
that matches the envisaged end product (DPI).
*NHS data
**Prof. G. Jenkins
https://gtr.ukri.org/project/0492A76A-AB08-4B22-9F18-6888FD732F00#/tabOverview
From June
NXP004
NXP004 represents novel forms of an undisclosed marketed oncology drug that has significant sales (more than £1 billion per annum in 2020) and is showing further growth. Nuformix filed one patent application on novel forms of this drug in 2020. Further outsourced research, through an expert contract organisation, on additional new forms and their properties has now commenced. If the research is positive, further patent applications may be filed.
From today
NXP004 patent application filing
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that it has filed a new patent application in relation to NXP004.
This filing covers a new family of co-crystalline forms of an undisclosed marketed drug that is approved globally for the treatment of several cancers and that had global sales of over £1bn in 2020. This is the second patent application related to NXP004 that Nuformix has filed and it complements the previous patent application on NXP004 co-crystals, thus expanding the Company's intellectual property portfolio.
Anne Brindley, Chief Executive Officer, Nuformix, commented: "We are pleased to have filed this new patent application for NXP004. Data that we have generated on these new co-crystal forms in the past six months has shown improvements over the marketed form that justifies filing this new application. This application, if granted, will strengthen the patent estate for NXP004 and Nuformix's IP portfolio as a whole."
Milwaukee - 11 November 2021: IQ-AI Limited (LSE: IQAI) (OTCQB: IQAIF), a developer of medical image processing platforms that have led to effective therapeutic strategies for brain tumor and other patients, and St. Jude Children's Hospital (Memphis, TN), have entered into a Data Use Agreement. The Agreement is a specific type of agreement required under the Health Insurance Portability and Accountability Act (HIPPA) Privacy Rule. It will provide Imaging Biometrics (IB) access to paediatric imaging datasets for use in the development of its patented, artificial intelligence (AI) technology, IB Zero G.
St. Jude Children's Hospital is the only National Cancer Institute (NCI)-designated Comprehensive Care Centre devoted solely to children. It has received the NCI's highest ranking of "exceptional" and has treated children from all 50 US states and from around the world.
Through this Agreement, IB will have access to a wide array of magnetic resonance (MR) datasets acquired in children of all ages. Diverse and accurately labelled (annotated) data are critical for developing and refining AI models. High quality data enables AI models to accurately analyze new, incoming, real-world image datasets. IB Zero G will use this data to generate synthetic contrast-enhanced images for paediatric neuro examinations.
Gadolinium Based Contrast Agents (GBCAs) have been used clinically in MRI examinations for decades and provide invaluable diagnostic information. In 2006, safety concerns were raised for GBCA use in patients due to the causative effect in a condition called nephrogenic systemic fibrosis (NSF). Since then, the awareness and understanding about GBCA use has escalated worldwide. More recently, it was found that repeated exposure of GBCAs result in its retention throughout the body. While the long-term adverse side effects are not known, the detrimental concerns for critical periods of life and especially on rapidly developing bone or brain, remain.
"This Agreement will accelerate the development and commercialization of IB Zero G," said Trevor Brown CEO of IQAI "Avoiding the use of GBCAs while preserving the diagnostic quality on paediatric images will help clinicians address concerns relating to GBCA retention and ultimately provide better care," he added.
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that Dr Alastair Riddell, currently Non-Executive Chairman, will assume the role of Executive Chairman with effect from 1 December 2021.
Lol!!
Chill flick the bean soup. I was just pointing out it’s not a good look to pretend you have inside information then gloat about it on a public bulletin board. Surprised the fun police haven’t removed the post!
Lol!!!
He didn’t get any leak, A broken clock is always right twice a day he spent 8 months saying the same thing so was bound to get it right sooner rather than later!! Exactly what he’s doing now! We are all awaiting the same thing it will come just wait!!
The guys just bonkers!! We are all fully aware news is due on 2 fronts to keep pretending you have inside info just makes you look stupid!! IMO!!
It will come when it comes and with how tight the ship now is I can’t see any leaks!! Spoke to my broker this morning and he agrees no leaks just retails p+d !!
Patience it will come!! Hopefully lol!!
January, February, and March (Q1)
April, May, and June (Q2)
July, August, and September (Q3)
October 31st, November, and December 31st(Q4)
So I would say we’re roughly half way through Q4 so updates anytime now!! Would like to see separate updates for each product to give double boost to the current share price. Would also like them to address the ceo situation ASAP as to avoid unneeded uncertainty!!
Hopefully not asking for too much!!
GLA!!!